News China clears its first drug for chronic hepatitis D Huahui Health has won the first approval in China for a drug to treat chronic infections with hepatitis D virus.
News AZ seeking $1.5bn in annual savings by end-2029 AstraZeneca has launched a cost-cutting programme that will aim to slash $1.5bn a year off its costs, with the savings reinvested in R&D.
Digital Sponsored Discover a new era of healthcare panel engagement: Grounded ... A new webinar from Konovo will address some of the critical topics impacting today’s healthcare market research industry.
